Plasma Cytokines/Chemokines as Predictive Biomarkers for Lymphedema in Breast Cancer Patients

SIMPLE SUMMARY: Lymphedema (LE) is characterized by arm, leg, trunk, or head/neck swelling, pain, depression, and cellulitis risk. Approximately 40% of breast cancer patients develop LE. Early LE diagnosis and treatment improve outcomes and minimize costs. As there is currently no cure, identifying predictive markers for breast cancer-related lymphedema (BCRL) could immensely reduce the financial burden on these patients and increase treatment success. This study identifies plasma cytokines/chemokines that predict BCRL development over a year before clinically recognized symptoms appear. ABSTRACT: Breast cancer-related lymphedema (BCRL) occurs in ~ 40% of patients after axillary lymph node dissection (ALND), radiation therapy (RT), or chemotherapy. First-line palliative treatment utilizes compression garments and specialized massage. Reparative microsurgeries have emerged as a second-line treatment, yet both compression and surgical therapy are most effective at early stages of LE development. Identifying patients at the highest risk for BCRL would allow earlier, more effective treatment. Perometric arm volume measurements, near-infrared fluorescent lymphatic imaging (NIRF-LI) data, and blood were collected between 2016 and 2021 for 40 study subjects undergoing treatment for breast cancer. Plasma samples were evaluated using MILLIPLEX human cytokine/chemokine panels at pre-ALND and at 12 months post-RT. A Mann–Whitney t-test showed that G-CSF, GM-CSF, IFN-2α, IL-10, IL-12p40, IL-15, IL-17A, IL-1β, IL-2, IL-3, IL-6, and MIP-1β were significantly higher at pre-ALND in those presenting with BCRL at 12 months post-RT. MIP-1β and IL-6 were significantly higher at pre-ALND in those who developed dermal backflow, but no BCRL, at 12 months post-RT. Plasma IL-15, IL-3, and MIP-1β were elevated at 12 months after RT in those with clinical BCRL. These findings establish BCRL as a perpetual inflammatory disorder, and suggest the use of plasma cytokine/chemokine levels to predict those at highest risk.